Background
Cristina Adriana Popa
Advance-HTN: Return of the systolic order – ...

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.

Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Background
swapnil hiremath
Double Trouble: ddAVP and the Bleeding Biopsy

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

Double Trouble: ddAVP and the Bleeding Biopsy
Background
Cristina Adriana Popa
Kidney Allografts-Play With Fire, Get Burned

This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…

Kidney Allografts-Play With Fire, Get Burned
Background
swapnil hiremath
Metformin- Should I Stay or Should I Go

This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Metformin- Should I Stay or Should I Go
Background
Brian Rifkin
KDIGO 2025 ADPKD Guidelines Review

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.


KDIGO 2025 ADPKD Guidelines Review

Next #NephJC is POSEIDAN from the Lancet

This study dropped a couple of weeks ago and we pushed up the list to go next week on NephJC.

Look for a full introduction on the NephJC home page in the next couple of days.

Programming Note: due to the fact that I want to remain married, we will be changing the date of the next #NephJC from Tuesday to Wednesday June 25th due to my 14th wedding anniversary.

Hangout #3 is in the can

We had a great discussion tonight with Joel and Swapnil being joined by the Dean of Sodium, Dr. Richard Sterns of the University of Rochester and Dr. Hatim Hassam of the University of Chicago. Check it out.

This is a follow up discussion from our Tweet Chat on June 10. Selected panelists will continue the conversation on the clinical practice guideline on diagnosis and treatment of hyponatraemia. This might be the first non-traditional subject for a journal club but it will not be the last.

When Dr. Goldfarb complains he gets results

We received his tweet

We replied with some snark

But then we fixed the page on the website.

Old website implying that hyponatremia is a sodium problem...

Old website implying that hyponatremia is a sodium problem...

...but any nephrologist worth his salt will tell you that hyponatremia is a water problem.

...but any nephrologist worth his salt will tell you that hyponatremia is a water problem.

And the winner is...

Last week we announced a contest to win a NephJC coffee mug

We had a surge of new people sign up for the newsletter and we have randomly selected a winner from this cohort. 

Marco Anaya Taboada of Bogota Columbia has won a NephJC mug. Now I just need to figure out how to ship one to South America.

Congratulations Marco!

Sign up for the NephJC Newsletter by going here.

Must read story about Renal Denervation in Europe

"Of course we need to reflect on and take in the key learnings from SYMPLICITY HTN-3, but why should one trial all of a sudden erase all of the other data?"

-- EuroPCR course codirector, Dr William Wijns

Wijns disclosed receiving institutional grant support from Abbott Vascular, Biosensors International, Biotronik, Boston Scientific, Cordis, Medtronic, and St Jude Medical

“It is difficult to get a man to understand something, when his salary depends on his not understanding it.”

-- Upton Sinclair

Great article by Shelley Wood tipped by John Mandrola